denkapparat Operations GmbH Acquires Shares of 9,416 Lantheus Holdings, Inc. $LNTH

denkapparat Operations GmbH bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,416 shares of the medical equipment provider’s stock, valued at approximately $1,045,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in LNTH. Farallon Capital Management LLC boosted its holdings in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after acquiring an additional 1,950,252 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $575,628,000. Reinhart Partners LLC. raised its stake in shares of Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion lifted its holdings in Lantheus by 18.4% in the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after buying an additional 206,000 shares during the period. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on LNTH shares. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. William Blair set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and cut their price target for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and reduced their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Trading Up 0.2%

LNTH opened at $100.98 on Friday. The firm’s fifty day moving average is $103.29 and its two-hundred day moving average is $92.69. The firm has a market cap of $6.59 billion, a PE ratio of 24.39 and a beta of -0.03. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.57 EPS. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.